Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue
| Autor: | Antonios Politis, Christos Cholevas, Theoharis C. Theoharides, Konstantinos Polyzoidis |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Encephalomyelitis Clinical Biochemistry coronavirus microglia Mast cell activation syndrome Inflammation mast cells Review Article chemotherapy Biochemistry Pathogenesis 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine COVID‐19 Chronic fatigue syndrome Medicine Humans brain fog Cognitive Dysfunction Luteolin Review Articles Neuroinflammation Microglia business.industry SARS-CoV-2 Brain COVID-19 General Medicine medicine.disease cytokines COVID-19 Drug Treatment 030104 developmental biology medicine.anatomical_structure chemistry inflammation 030220 oncology & carcinogenesis Immunology Molecular Medicine fatigue medicine.symptom business |
| Zdroj: | Biofactors (Oxford, England) |
| ISSN: | 1872-8081 |
| Popis: | COVID‐19 leads to severe respiratory problems, but also to long‐COVID syndrome associated primarily with cognitive dysfunction and fatigue. Long‐COVID syndrome symptoms, especially brain fog, are similar to those experienced by patients undertaking or following chemotherapy for cancer (chemofog or chemobrain), as well in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) or mast cell activation syndrome (MCAS). The pathogenesis of brain fog in these illnesses is presently unknown but may involve neuroinflammation via mast cells stimulated by pathogenic and stress stimuli to release mediators that activate microglia and lead to inflammation in the hypothalamus. These processes could be mitigated by phytosomal formulation (in olive pomace oil) of the natural flavonoid luteolin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text